Cargando…

Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation

OBJECTIVE: Elevated very low-density lipoprotein (VLDL)-triglyceride (TG) secretion from the liver contributes to an atherogenic dyslipidemia that is associated with obesity, diabetes and the metabolic syndrome. Numerous models of obesity and diabetes are characterized by increased central nervous s...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, Jennifer M., Bruinstroop, Eveline, Printz, Richard L., Alijagic-Boers, Aldijana, Foppen, Ewout, Turney, Maxine K., George, Leena, Beck-Sickinger, Annette G., Kalsbeek, Andries, Niswender, Kevin D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338317/
https://www.ncbi.nlm.nih.gov/pubmed/25737956
http://dx.doi.org/10.1016/j.molmet.2015.01.004
_version_ 1782481191092355072
author Rojas, Jennifer M.
Bruinstroop, Eveline
Printz, Richard L.
Alijagic-Boers, Aldijana
Foppen, Ewout
Turney, Maxine K.
George, Leena
Beck-Sickinger, Annette G.
Kalsbeek, Andries
Niswender, Kevin D.
author_facet Rojas, Jennifer M.
Bruinstroop, Eveline
Printz, Richard L.
Alijagic-Boers, Aldijana
Foppen, Ewout
Turney, Maxine K.
George, Leena
Beck-Sickinger, Annette G.
Kalsbeek, Andries
Niswender, Kevin D.
author_sort Rojas, Jennifer M.
collection PubMed
description OBJECTIVE: Elevated very low-density lipoprotein (VLDL)-triglyceride (TG) secretion from the liver contributes to an atherogenic dyslipidemia that is associated with obesity, diabetes and the metabolic syndrome. Numerous models of obesity and diabetes are characterized by increased central nervous system (CNS) neuropeptide Y (NPY); in fact, a single intracerebroventricular (icv) administration of NPY in lean fasted rats elevates hepatic VLDL-TG secretion and does so, in large part, via signaling through the CNS NPY Y1 receptor. Thus, our overarching hypothesis is that elevated CNS NPY action contributes to dyslipidemia by activating central circuits that modulate liver lipid metabolism. METHODS: Chow-fed Zucker fatty (ZF) rats were pair-fed by matching their caloric intake to that of lean controls and effects on body weight, plasma TG, and liver content of TG and phospholipid (PL) were compared to ad-libitum (ad-lib) fed ZF rats. Additionally, lean 4-h fasted rats with intact or disrupted hepatic sympathetic innervation were treated with icv NPY or NPY Y1 receptor agonist to identify novel hepatic mechanisms by which NPY promotes VLDL particle maturation and secretion. RESULTS: Manipulation of plasma TG levels in obese ZF rats, through pair-feeding had no effect on liver TG content; however, hepatic PL content was substantially reduced and was tightly correlated with plasma TG levels. Treatment with icv NPY or a selective NPY Y1 receptor agonist in lean fasted rats robustly activated key hepatic regulatory proteins, stearoyl-CoA desaturase-1 (SCD-1), ADP-ribosylation factor-1 (ARF-1), and lipin-1, known to be involved in remodeling liver PL into TG for VLDL maturation and secretion. Lastly, we show that the effects of CNS NPY on key liporegulatory proteins are attenuated by hepatic sympathetic denervation. CONCLUSIONS: These data support a model in which CNS NPY modulates mediators of hepatic PL remodeling and VLDL maturation to stimulate VLDL-TG secretion that is dependent on the Y1 receptor and sympathetic signaling to the liver.
format Online
Article
Text
id pubmed-4338317
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-43383172015-03-03 Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation Rojas, Jennifer M. Bruinstroop, Eveline Printz, Richard L. Alijagic-Boers, Aldijana Foppen, Ewout Turney, Maxine K. George, Leena Beck-Sickinger, Annette G. Kalsbeek, Andries Niswender, Kevin D. Mol Metab Original Article OBJECTIVE: Elevated very low-density lipoprotein (VLDL)-triglyceride (TG) secretion from the liver contributes to an atherogenic dyslipidemia that is associated with obesity, diabetes and the metabolic syndrome. Numerous models of obesity and diabetes are characterized by increased central nervous system (CNS) neuropeptide Y (NPY); in fact, a single intracerebroventricular (icv) administration of NPY in lean fasted rats elevates hepatic VLDL-TG secretion and does so, in large part, via signaling through the CNS NPY Y1 receptor. Thus, our overarching hypothesis is that elevated CNS NPY action contributes to dyslipidemia by activating central circuits that modulate liver lipid metabolism. METHODS: Chow-fed Zucker fatty (ZF) rats were pair-fed by matching their caloric intake to that of lean controls and effects on body weight, plasma TG, and liver content of TG and phospholipid (PL) were compared to ad-libitum (ad-lib) fed ZF rats. Additionally, lean 4-h fasted rats with intact or disrupted hepatic sympathetic innervation were treated with icv NPY or NPY Y1 receptor agonist to identify novel hepatic mechanisms by which NPY promotes VLDL particle maturation and secretion. RESULTS: Manipulation of plasma TG levels in obese ZF rats, through pair-feeding had no effect on liver TG content; however, hepatic PL content was substantially reduced and was tightly correlated with plasma TG levels. Treatment with icv NPY or a selective NPY Y1 receptor agonist in lean fasted rats robustly activated key hepatic regulatory proteins, stearoyl-CoA desaturase-1 (SCD-1), ADP-ribosylation factor-1 (ARF-1), and lipin-1, known to be involved in remodeling liver PL into TG for VLDL maturation and secretion. Lastly, we show that the effects of CNS NPY on key liporegulatory proteins are attenuated by hepatic sympathetic denervation. CONCLUSIONS: These data support a model in which CNS NPY modulates mediators of hepatic PL remodeling and VLDL maturation to stimulate VLDL-TG secretion that is dependent on the Y1 receptor and sympathetic signaling to the liver. Elsevier 2015-01-16 /pmc/articles/PMC4338317/ /pubmed/25737956 http://dx.doi.org/10.1016/j.molmet.2015.01.004 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Rojas, Jennifer M.
Bruinstroop, Eveline
Printz, Richard L.
Alijagic-Boers, Aldijana
Foppen, Ewout
Turney, Maxine K.
George, Leena
Beck-Sickinger, Annette G.
Kalsbeek, Andries
Niswender, Kevin D.
Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation
title Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation
title_full Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation
title_fullStr Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation
title_full_unstemmed Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation
title_short Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation
title_sort central nervous system neuropeptide y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338317/
https://www.ncbi.nlm.nih.gov/pubmed/25737956
http://dx.doi.org/10.1016/j.molmet.2015.01.004
work_keys_str_mv AT rojasjenniferm centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation
AT bruinstroopeveline centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation
AT printzrichardl centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation
AT alijagicboersaldijana centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation
AT foppenewout centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation
AT turneymaxinek centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation
AT georgeleena centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation
AT becksickingerannetteg centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation
AT kalsbeekandries centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation
AT niswenderkevind centralnervoussystemneuropeptideyregulatesmediatorsofhepaticphospholipidremodelingandverylowdensitylipoproteintriglyceridesecretionviasympatheticinnervation